BioGaia AB Reports Mixed Financial Results and Strategic Expansion

BioGaia AB ( ($SE:BIOG.B) ) has issued an update.

BioGaia AB reported a modest increase in net sales for the first half of 2025, with significant growth in the Adult Health segment. However, operating profit and profit after tax both saw declines, attributed to increased operating expenses. The company is expanding its global presence with direct sales in the Netherlands and has launched a new subsidiary, BioGaia New Sciences AB, to advance microbiome research.

More about BioGaia AB

BioGaia AB is a company operating in the probiotics industry, focusing on the development and sale of probiotic products aimed at improving health. The company primarily targets the Pediatrics and Adult Health segments, with a market focus on expanding its global footprint.

Average Trading Volume: 201,627

Current Market Cap: SEK10.97B

For an in-depth examination of BIOG.B stock, go to TipRanks’ Overview page.